| 引用本文:冯娟1，闫奎坡2，朱翠玲2，孙彦琴2，郭雨晴1，徐亚洲2，刘晓萌1.基于随机对照试验系统评价脑心通胶囊治疗冠心病心绞痛的疗效[J].世界中医药,2021,(18):. |
|
| 基于随机对照试验系统评价脑心通胶囊治疗冠心病心绞痛的疗效 |
| Systematic Review of the Efficacy of Naoxintong Capsule in Treating Coronary Heart Disease with Angina Pectoris Based on Randomized Controlled Trials |
| 投稿时间：2020-01-14 |
| DOI：10.3969/j.issn.1673-7202.2021.18.011 |
| 中文关键词: 脑心通胶囊 冠心病 心绞痛 血脂 血流变 不良反应 系统评价 |
| English Keywords:Naoxintong Capsule Coronary Heart Disease Angina Pectoris Blood lipids Blood rheology Adverse reactions Systematic review |
| 基金项目:国家自然科学基金青年基金项目(81303073);河南省科技攻关项目(192102310161,182102310291) |
|
| 摘要点击次数: 259 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的:评价脑心通胶囊治疗冠心病心绞痛的疗效及对血脂、血液流变学的影响。方法:全面检索PubMed、Cochrane Library、EMBase、国家知识基础设施数据库(CNKI)、中国学术期刊数据库(CSPD)、中文科技期刊数据库(CCD)、中国生物医学文献(CBM)从建库至2019年12月已发表的相关文献,对收集数据进行效应量合并,采用RevMan5.3进行Meta分析。结果:最终纳入26篇文献,4 380例受试者;脑心通胶囊联合西药能显著提高患者心绞痛疗效(RR=0.43,95%CI为0.36~0.52,Z＝8.87,P<0.000 01)、心电图疗效(RR=0.48,95%CI为0.41~0.57,Z＝8.90,P<0.000 01)和临床总疗效(RR=0.27,95%CI为0.13~0.57,Z＝3.47,P=0.0005);降低TC(MD=-0.80,95%CI为-0.94～-0.67,Z＝12.04,P<0.000 01)、TG(MD=-0.44,95%CI为-0.56～-0.32,Z＝7.00,P<0.000 01)、LDL(MD=-0.44,95%CI为-0.53～-0.35,Z＝9.61,P<0.000 01);升高HDL(MD=0.13,95%CI为0.07~0.19,Z＝4.00,P<0.000 1);降低全血黏度高切(MD=-1.22,95%CI为-1.69～-0.75,Z＝5.08,P<0.000 1)、低切(MD=-2.38,95%CI为-3.52～-1.23,Z＝4.06,P<0.000 1)、血浆黏度(MD=-0.31,95%CI为-0.40～-0.21,Z＝6.36,P<0.000 01);且不增加不良反应(RR=1.29,95%CI为0.56~2.98),Z＝0.60,P=0.55)。结论:与西药比较,脑心通胶囊联合西药具有良好的降血脂、改善血液流变学的作用,能显著改善患者临床疗效,减少心绞痛发作次数和持续时间,且无明显的不良反应。 |
| English Summary: |
| To evaluate the efficacy on blood lipids and hemorheology of Naoxintong Capsule in the treatment of coronary heart disease with angina pectoris.Methods:Literatures in Pubmed，Cochrane Library，EMBase，CNKI，CSPD，CCD，CBM databases were searched to obtain available clinical trials from the establishment of the database to December 2019.Meta analysis was then performed by RevMan5.3.Results:There were 26 articles and 4380 patients included.Naoxintong Capsule combined with western medicine can improve the effect of angina Pectoris(RR=0.43，95%CI 0.36 to 0.52)，Z=8.87，P<0.000 01)，ECG(RR=0.48，95%CI 0.41 to 0.57 Z=8.90，P<0.000 01) and total clinical efficacy(RR=0.27，95%CI 0.13 to 0.57，Z=3.47，P=0.000 5); reduced TC(MD=-0.80，95%CI -0.94 to -0.67，Z=12.04，P<0.000 01)，TG(MD=-0.44，95%CI -0.56 to -0.32，Z=7.00，P<0.000 01)，LDL(MD=-0.44，95%CI -0.53 to -0.35，Z=9.61，P<0.000 01); increased HDL(MD=0.13，95%CI 0.07 to 0.19，Z=4.00，P<0.000 1); reduced whole blood viscosity high cut(MD=-1.22，95%CI -1.69 to -0.75，Z=5.08，P<0.000 01)，low cut(MD=-2.38，95%CI -3.52 to -1.23，Z=4.06，P<0.000 1)，plasma viscosity(MD=-0.31，95%CI -0.40 to -0.21，Z=6.36，P<0.000 01)，and adverse reactions not increased(RR=1.29，95%CI 0.56 to 2.98，Z=0.60，P=0.55).Conclusion:Compared with western medicine，Naoxintong capsule combined with western medicine has a favorable effect on lowering blood lipid and improving blood rheology，which significantly improves the clinical efficacy，reduces the frequency and duration of angina pectoris with no obvious adverse reactions. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
